uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Mucosal Cytokine Profiles After Induction Therapy With Granulocyte/Monocyte Apheresis in New-onset Inflammatory Colitis
Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Huddinge, Sweden.;Karolinska Inst, Sodersjukhuset, Sachs Children & Youth Hosp, Dept Gastroenterol, Huddinge, Sweden..
Karolinska Inst, Dept Med, Huddinge, Sweden.;Karolinska Univ Hosp, Clin Immunol & Transfus Med, Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centre for Clinical Research, County of Västmanland. Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.
Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Huddinge, Sweden.;Danderyd Hosp, Dept Gastroenterol, Stockholm, Sweden..
Show others and affiliations
2018 (English)In: Journal of Pediatric Gastroenterology and Nutrition - JPGN, ISSN 0277-2116, E-ISSN 1536-4801, Vol. 66, no 4, p. E103-E107Article in journal (Refereed) Published
Abstract [en]

Granulocyte/monocyte apheresis (GMA) selectively removes circulating granulocytes and monocytes; important producers of proinflammatory cytokines. Seven children with new-onset inflammatory bowel disease (IBD) colitis were treated with GMA together with mesalazine, and had significant decreases in Pediatric UC Activity Index (P=0.018) and Mayo endoscopic score (P=0.013). We investigated the colonic mucosal cytokine profiles (analyzed with real-time polymerase chain reaction), before and after induction treatment, and in 6 non-IBD controls. Significant decreases were seen in Colony Stimulating Factor 2 (P=0.018), tumor necrosis factor- (P=0.028), interleukin (IL)-23 (P=0.043), IL-1 (P=0.028), IL-36 (P=0.018), IL-10 (P=0.028), and transforming growth factor beta 1 (P=0.043) after treatment. In 6 non-IBD controls there were significantly lower levels of IL-12 (P=0.023) and IL-23 (P=0.046) compared to the patients with IBD at onset, and IL-22 (P=0.088) and IL-36 (P=0.062) showed lower values without reaching significant differences. We speculate that the decreases in colonic mucosal cytokine profiles after treatment may explain the observed clinical efficacy in the GMA-treated children with IBD.

Place, publisher, year, edition, pages
2018. Vol. 66, no 4, p. E103-E107
Keywords [en]
children, colonic cytokines, granulocyte, monocyte apheresis, new inflammatory bowel disease, remission induction therapy
National Category
Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:uu:diva-351641DOI: 10.1097/MPG.0000000000001735ISI: 000429050500003PubMedID: 28891831OAI: oai:DiVA.org:uu-351641DiVA, id: diva2:1211621
Available from: 2018-05-31 Created: 2018-05-31 Last updated: 2018-05-31Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Fagerberg, Ulrika L.

Search in DiVA

By author/editor
Fagerberg, Ulrika L.
By organisation
Centre for Clinical Research, County of Västmanland
In the same journal
Journal of Pediatric Gastroenterology and Nutrition - JPGN
Gastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf